Effet du firocoxib sur la cicatrisation articulaire après TPLO chez le chien

Cette étude compare les effets du firocoxib administré 120 j vs 30 j après chirurgie articulaire sur les signes cliniques et les lésions arthrosiques chez le chien

Intranasal melanoma treated with radiation therapy in three dogs

Three dogs were investigated for chronic unilateral nasal discharge. In all cases CT imaging showed an intranasal mass causing turbinate lysis and no evidence of metastasis. Cytology in cases 1 (a 14-year-old neutered male crossbreed dog) and 2 (a five-year-old neutered male German Shepherd dog) demonstrated a pleomorphic cell population with variable intracellular pigment suspicious of melanocytic neoplasia. Histopathology with immunohistochemistry (Melan-A and vimentin, plus PNL-2 in one case) confirmed the diagnosis of melanoma in all dogs. All dogs were treated with megavoltage radiotherapy using linear accelerators. Cases 1 and 3 (a nine-year-old neutered female beagle dog) received a hypofractionated (4 × 8 Gy) protocol and case 2 received a definitive (12 × 4 Gy) protocol. Complete remission was demonstrated on repeat CT scan five months after diagnosis in case 1 and seven months in case 2. Stable disease was documented on CT at four months for case 3; however, clinical signs in this dog remained controlled for 10 months in total. Case 1 died of unrelated causes five months after diagnosis, case 2 was euthanased due to the development of seizures 13 months after diagnosis, and case 3 was lost to follow-up 12 months after diagnosis. Melanoma should be considered as a rare differential diagnosis for primary nasal neoplasia in the dog and radiation therapy can be used as effective local therapy

Caractère chronique de l’arthrose et rôle des AINS dans sa prise en charge chez le chien

La mécompréhension du caractère chronique de l’arthrose est à l’origine de difficultés dans sa prise en charge, bien que de nombreux traitements soient disponibles

Enfermedad degenerativa articular en caninos

La Enfermedad Degenerativa Articular es también conocida como osteoartritis se presenta en todos los mamíferos donde se incluye la especie canina, con un origen multifactorial. La cual se caracteriza por ser una enfermedad de manifestación dolorosa, progresiva y limitante en perros mayores de un año. Tradicionalmente su diagnostico se ha basado en el examen clínico y el uso de la radiología como ayuda diagnostica. Así mismo su tratamiento está enfocado en controlar el dolor donde se deja de lado el proceso degenerativo que afecta el cartílago articular. El propósito del presente texto monográfico es dar a conocer la enfermedad degenerativa articular, donde se abordara su fisiopatología, diagnostico y tratamiento mediante la revisión de la bibliografía disponible. El cual aporta, un panorama sobre nuevos enfoques actuales en cuanto al uso de herramientas que permitan realizar un diagnostico temprano de la enfermedad, al igual que el uso de diferentes medios terapéuticos que no dependan tanto del uso de analgésicos antiinflamatorios para controlar el dolor y mejorar la movilidad, sino de terapias que permitan la regeneración de la articulación, en especial la articulación como tal. Como lo es el uso de células madre entre otros, que según los artículos citados demuestran ese panorama exitoso aunque aun falte mucho por investigar

Axial Multicentric Osteosarcoma in an English Cocker Spaniel

No abstract available

Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.

BackgroundReported response rates of transitional cell carcinoma (TCC) in dogs to piroxicam in combination with either mitoxantrone or carboplatin are similar; however, it is unknown whether either drug might provide superior duration of response.Hypothesis/objectivesTo determine if the progression-free interval (PFI) of dogs with TCC treated with mitoxantrone and piroxicam was different than that of dogs receiving carboplatin and piroxicam. The hypothesis was that the efficacy of mitoxantrone is no different from carboplatin.AnimalsFifty dogs with TCC without azotemia.MethodsProspective open-label phase III randomized study. Either mitoxantrone or carboplatin was administered every 3 weeks concurrently with piroxicam with restaging at 6-week intervals. Twenty-four dogs received carboplatin and 26 received mitoxantrone.ResultsResponse was not different between groups (P = .56). None of the dogs showed complete response. In the mitoxantrone group, there were 2 (8%) partial responses (PR) and 18 (69%) dogs with stable disease (SD). In the carboplatin group, there were 3 PR (13%) and 13 (54%) dogs with SD. The PFI was not significantly different between groups (mitoxantrone = 106 days; carboplatin = 73.5 days; P = .62; hazard ratio 0.86; 95% confidence interval 0.47-1.56). Dogs with prostatic involvement experienced a shorter survival (median, 109 days) compared to dogs with urethral, trigonal, or apically located tumors; this difference was significant (median 300, 190, and 645 days, respectively; P = .005).Conclusions and clinical importanceThis study did not detect a different in outcome in dogs with TCC treated with either mitoxantrone or carboplatin in combination with piroxicam

Clinical Investigators' Day, October 10, 2014

Contents of this program booklet includes: Sponsors; Program Schedule; Keynote Speaker (Maria Constanca Matias Ferreira Pomba); Speakers [faculty bio sketches]; Judges [bio sketches]; Moderators [bio sketches]; Investigators [bio sketches]